SAN JOSE, Calif.–(BUSINESS WIRE)–VSee Health, Inc. (Nasdaq: VSEE), a leader in comprehensive digital health services and customized telehealth workflow streams, has been awarded a significant contract with a prominent, innovative health system in Florida valued at approximately $160,000. The contract value would grow significantly if deployment broadens. This partnership underscores VSee Health’s commitment to revolutionizing healthcare delivery through customized telehealth solutions that se

NASHVILLE, Tenn.–(BUSINESS WIRE)–Nashville Biosciences LLC (NashBio), a leading real-world, multi-omics data company, today announced the launch of multiple next-generation, real-world data (RWD) solutions, including a research platform and therapeutic area collections over the next 6 months. These advancements will deliver unprecedented access to deidentified electronic health record (EHR) and linked genomic data, empowering life science researchers, pharmaceutical companies, and biotech inn

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD). The repeat dose study is a small exploratory U.S. Phase 2 multi-center, randomized, double-blind, place

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per share. All of the shares are being offered by Amylyx. In addition, Amylyx has granted the underwriter a 30-day option to purchase up to an additional 2,571,428 shares of its common stock at the public offering price per share, less underwriting dis

DUBLIN–(BUSINESS WIRE)–The “Preclinical Contract Research Organizations – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Preclinical Contract Research Organizations was estimated at US$7.1 Billion in 2023 and is projected to reach US$11.3 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed bus

GLASGOW, Scotland–(BUSINESS WIRE)– #Chemify–Chemify hires biopharma veteran Dr. Alastair Leighton as Chief Operating Officer.

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025. “With our team’s innovation and execution throughout 2024, Rallybio is well positioned to create meaningful value in 2025,” said Stephen Uden, M.D., Chief Executive Officer of Rallybi